What is the primary purpose of the 8-K filing?

The primary purpose of this 8-K filing is to report a material definitive agreement regarding an amendment to Regeneron's 2000 Long-Term Incentive Plan, which includes a proposed Option Exchange Program, and to inform investors that shareholder approval will be sought.

What is the Option Exchange Program?

The Option Exchange Program is a one-time opportunity for eligible employees to exchange certain existing stock options for a smaller number of new stock options. These new options will have an exercise price that is set at the fair market value of the company's common stock on the date the new options are granted.

What is required for this amendment to become effective?

The amendment to the 2000 Long-Term Incentive Plan, including the Option Exchange Program, requires approval from Regeneron's shareholders. A Special Meeting will be held for this purpose, and if the shareholders do not approve the proposal, the amendment will be void.

How does this affect existing shareholders?

For existing shareholders, the key impact is the potential dilution from the issuance of new stock options. The exchange program aims to reset the exercise price for certain outstanding options, which could be seen as a retention tool for employees. Investors should review the proxy statement for details on the potential number of shares involved and the implications for the share count.

REGN 8-K: Material Agreements

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced on November 17, 2004, a proposed amendment to its 2000 Long-Term Incentive Plan (the "2000 Plan"), subject to shareholder approval. This amendment would introduce a one-time Option Exchange Program for eligible employees. Under this program, employees can exchange certain existing stock options for a reduced number of new options. These replacement options will have an exercise price equal to the fair market value of the Company's Common Stock on the grant date of the replacement options. The company has filed a preliminary proxy statement for a Special Meeting of shareholders to vote on this amendment, and its approval is crucial for the amendment to become effective.

Key Highlights

1Regeneron is proposing an amendment to its 2000 Long-Term Incentive Plan.
2The proposed amendment introduces a one-time Option Exchange Program.
3Eligible employees can exchange existing stock options for a lesser number of new options.
4Replacement options will have an exercise price based on the fair market value at the grant date of the new options.
5Shareholder approval is required for the amendment to take effect.
6A preliminary proxy statement has been filed for a Special Meeting of shareholders to vote on the proposal.
7If not approved, the amendment will be void from the beginning.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Material Agreement (Nov 17, 2004)

Summary

Key Highlights

Frequently Asked Questions